Recent advancements in CRISPR‐Cas9 gene‐editing technologies targeting EGFR, survivin, and Nrf2 genes offer promising potential for GPC3‐targeted HCC therapy.[13] Ribonucleoproteins (RNP) complexes, composed of the Cas9 protein and a single guide RNA (sgRNA), provide significant advantages over mRNA‐based delivery. This evidence concerns the gene GPC3 and hepatocellular carcinoma.